EC Number   |
Application |
Reference |
|---|
   2.3.2.5 | drug development |
development of hQC enzyme inhibitors, 5,6-dimethoxy-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1Hbenzo[d]imidazol-2-amine is a potential drug for treatment of Alzheimer's disease |
760123 |
| 2.3.2.5 | drug development |
development of small molecule inhibitors of glutaminyl cyclase and isoglutaminyl cyclase for Alzheimers disease |
759074 |
| 2.3.2.5 | drug development |
glutaminyl cyclase is a drug target to diminish pE-Abeta formation |
759804 |
| 2.3.2.5 | drug development |
QCT would be suitable for enzyme therapy in gluten intolerance and appear to have synergistic action with porcine intestinal extracts, potential for enzyme therapy in coeliac disease |
695532 |
| 2.3.2.5 | drug development |
the enzyme is a potential target for the development of novel anti-Alzheimer disease agents. Phenol-40 (R1-), C5-OH (R2-) and C7-OH (R3-) modified apigenin derivatives are synthesized and evaluated as another class of human QC (hQC) inhibitors |
758904 |
| 2.3.2.5 | medicine |
hQC isozymes, sQC and gQC, inhibition is considered to be an attractive strategy to prevent the formation of pGlu-Abeta and to reduce neuroinflammation and provides an opportunity for the treatment of Alzheimer disease |
759909 |
| 2.3.2.5 | medicine |
inhibition of glutaminyl cyclase offers a new therapeutic option for the treatment of Alzheimers disease and provides implications for other amyloidoses, such as familial Danish dementia |
689131 |
| 2.3.2.5 | medicine |
the development of hQC enzyme inhibitors can prevent the self-aggregation of Abeta peptides, resulting in impeding Alzheimer's disease |
760123 |
| 2.3.2.5 | medicine |
the enzyme is a pharmacological target for Alzheimers disease therapy |
718521 |
| 2.3.2.5 | pharmacology |
Abeta38, Abeta40 and angiogenesis mediators Flt1, Tie2, VEGFD, CAM-1 and ICAM-1 are potential pharmacodynamic markers of glutaminyl cyclase (QC) inhibition, because their levels closely correlate with QC activity in Alzheimer's disease patients. The addition of QC activity to core diagnostic cerebrospinal fluid (CSF) biomarkers may be of specific interest in clinical cases with discordant imaging and biochemical biomarker results. Core CSF diagnostic biomarkers (Abeta42, tau and p-tau) are not part of the diagnostic workup |
758620 |
